Protective mechanisms of ischemic postconditioning

缺血后处理的保护机制

基本信息

  • 批准号:
    8118824
  • 负责人:
  • 金额:
    $ 33.95万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-09-01 至 2015-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The current lack of effective treatments for acute stroke necessitates exploring innovative concepts that may eventually lead to clinical applications. One such technique is ischemic postconditioning. We have demonstrated that both rapid and delayed ischemic postconditioning reduces infarction in rats. Stroke was induced by a 30 min bCCA occlusion plus permanent distal middle cerebral artery (MCA) occlusion. The bCCA release allows partial reperfusion, which mimics the frequent clinical cases that occur in stroke patients. Rapid postconditioning is applied immediately after reperfusion while delayed postconditioning is conducted 5.5 h after reperfusion. Despite confirmation of the protective effects of postconditioning by several independent research groups, the underlying protective mechanisms are not understood. We have preliminary data showing that rapid postconditioning attenuates reactive oxygen species (ROS) activity, suggesting a correlation between postconditioning and ROS reduction. Whether ROS reduction truly contributes to postconditioning's protective effects is not known. In addition, ROS activity directly results in dysfunction of the neuronal survival signaling pathway, Akt/PRAS40 pathway, and Akt dysfunction leads to inflammation. However, the roles of the Akt/PRAS40 pathway and inflammation in the protective effects of ischemic postconditioning have not been well studied. In this grant, we will first identify subcellular sources of ROS activity that are involved in postconditioning's protective effects. We will then study the relationship between ROS reduction and Akt/PRAS40 activity in both rats and PRAS40 knockout mice, which has never been used in any studies. Finally, we will study how Akt/PRAS40 regulates the inflammatory response, including its effects on the pro-inflammatory factors HMGB1 and Cox-2, and the novel galectin-9/Tim-3 inflammatory pathway. Through these studies, we will fill significant gaps in our knowledge about the protective mechanisms and clinical translation of ischemic postconditioning. Specific Aim 1. To identify the subcellular regulatory sources of ROS reduction that play critical roles in the protective effects of ischemic postconditioning. Specific Aim 2. To study whether ROS inhibition improves the Akt/PRAS40 activity. Specific Aim 3. To examine the protective effects of the Akt/PRAS40 pathway on the pro-inflammatory response of HMGB1 and Cox-2, and the galectin-9/Tim-3 inflammatory pathway. PUBLIC HEALTH RELEVANCE: Both rapid and delayed postconditioning after stroke reduce ischemic damage, opening up a new avenue for research in stroke treatment, which may eventually be clinically applicable for stroke patients.
描述(由申请人提供):目前缺乏有效的急性中风治疗方法,需要探索创新的概念,最终可能导致临床应用。其中一种技术是缺血后适应。我们已经证明快速和延迟的缺血后适应都可以减少大鼠的梗死。脑卒中是由30分钟bCCA闭塞加永久性大脑中远端动脉(MCA)闭塞引起的。bCCA释放允许部分再灌注,模仿中风患者常见的临床病例。再灌注后立即进行快速后处理,再灌注后5.5 h进行延迟后处理。尽管几个独立的研究小组证实了后处理的保护作用,但其潜在的保护机制尚不清楚。我们有初步的数据表明,快速后适应会降低活性氧(ROS)的活性,这表明后适应与ROS减少之间存在相关性。ROS的减少是否真的有助于后处理的保护作用尚不清楚。此外,ROS活性直接导致神经元存活信号通路Akt/PRAS40通路功能障碍,Akt功能障碍导致炎症。然而,Akt/PRAS40通路和炎症在缺血后适应保护作用中的作用尚未得到很好的研究。在本研究中,我们将首先确定参与后处理保护作用的活性氧活性的亚细胞来源。然后,我们将在大鼠和PRAS40敲除小鼠中研究ROS减少与Akt/PRAS40活性之间的关系,这在任何研究中都没有使用过。最后,我们将研究Akt/PRAS40如何调节炎症反应,包括其对促炎因子HMGB1和Cox-2的影响,以及新的半乳糖凝集素-9/Tim-3炎症通路。通过这些研究,我们将填补我们在缺血后适应的保护机制和临床翻译方面的重大空白。具体目标确定在缺血后适应保护作用中起关键作用的ROS减少的亚细胞调控来源。具体目标2。研究ROS抑制是否能提高Akt/PRAS40活性。具体目标3。探讨Akt/PRAS40通路对HMGB1和Cox-2的促炎反应以及半乳糖凝集素-9/Tim-3炎症通路的保护作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HENG ZHAO其他文献

HENG ZHAO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HENG ZHAO', 18)}}的其他基金

Protective mechanisms of ischemic postconditioning
缺血后处理的保护机制
  • 批准号:
    8269944
  • 财政年份:
    2010
  • 资助金额:
    $ 33.95万
  • 项目类别:
Protective mechanisms of ischemic postconditioning
缺血后处理的保护机制
  • 批准号:
    8474850
  • 财政年份:
    2010
  • 资助金额:
    $ 33.95万
  • 项目类别:
Protective mechanisms of ischemic postconditioning
缺血后处理的保护机制
  • 批准号:
    8677978
  • 财政年份:
    2010
  • 资助金额:
    $ 33.95万
  • 项目类别:
Protective mechanisms of ischemic postconditioning
缺血后处理的保护机制
  • 批准号:
    7986790
  • 财政年份:
    2010
  • 资助金额:
    $ 33.95万
  • 项目类别:
Postconditioning reduces ischemic damage after stroke in rats
后处理可减少大鼠中风后的缺血性损伤
  • 批准号:
    7469909
  • 财政年份:
    2008
  • 资助金额:
    $ 33.95万
  • 项目类别:
Protective mechanisms of ischemic postconditioning
缺血后处理的保护机制
  • 批准号:
    9490443
  • 财政年份:
    2008
  • 资助金额:
    $ 33.95万
  • 项目类别:
Postconditioning reduces ischemic damage after stroke in rats
后处理可减少大鼠中风后的缺血性损伤
  • 批准号:
    7689221
  • 财政年份:
    2008
  • 资助金额:
    $ 33.95万
  • 项目类别:

相似海外基金

Development of Enhanced Anti-inflammatory Blood Mononuclear Cell Therapy for ARDS and Elucidation of the Molecular Mechanism
ARDS增强抗炎血液单核细胞治疗的进展及分子机制的阐明
  • 批准号:
    23K07659
  • 财政年份:
    2023
  • 资助金额:
    $ 33.95万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Exploring therapeutic effects of anti-inflammatory and resolving factors in osteoporosis model mice
探讨抗炎和缓解因子对骨质疏松模型小鼠的治疗作用
  • 批准号:
    23K15705
  • 财政年份:
    2023
  • 资助金额:
    $ 33.95万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Investigation of the relation between age-related estradiol fluctuation and pro-/anti-inflammatory effects in transplant immune response.
研究年龄相关雌二醇波动与移植免疫反应中促/抗炎作用之间的关系。
  • 批准号:
    23K19490
  • 财政年份:
    2023
  • 资助金额:
    $ 33.95万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Non-coating anti-microbial, anti-host protein deposition, anti-inflammatory urinary catheter
无涂层抗菌、抗宿主蛋白沉积、抗炎导尿管
  • 批准号:
    10697567
  • 财政年份:
    2023
  • 资助金额:
    $ 33.95万
  • 项目类别:
Identification and optimization of verapamil as a novel neuroprotective and anti-inflammatory agent for reducing long-term neurological morbidities following organophosphate-induced status epilepticus
维拉帕米作为新型神经保护和抗炎剂的鉴定和优化,用于减少有机磷引起的癫痫持续状态后的长期神经系统发病率
  • 批准号:
    10727765
  • 财政年份:
    2023
  • 资助金额:
    $ 33.95万
  • 项目类别:
Anti-inflammatory Effects of Hydrogen Gas Produced by Gut Microflora in a Mouse Model of ARDS
肠道菌群产生的氢气对 ARDS 小鼠模型的抗炎作用
  • 批准号:
    23K08467
  • 财政年份:
    2023
  • 资助金额:
    $ 33.95万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Knockdown of AdipoR2 Compromises Adiponectin’s Anti-inflammatory Actions by Mainly Promoting a Pro-inflammatory Chemokine and Cytokine Secretory Profile in THP-1 Macrophages
AdipoR2 的敲低主要通过促进 THP-1 巨噬细胞中促炎趋化因子和细胞因子的分泌特征来损害脂联素的抗炎作用
  • 批准号:
    493138
  • 财政年份:
    2023
  • 资助金额:
    $ 33.95万
  • 项目类别:
Elucidation of anti-inflammatory mechanism of surface layer protein of lactic acid bacteria focusing on its interaction with lipopolysaccharide.
阐明乳酸菌表面层蛋白的抗炎机制,重点关注其与脂多糖的相互作用。
  • 批准号:
    23K13905
  • 财政年份:
    2023
  • 资助金额:
    $ 33.95万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
SBIR Phase I: Structure-guided design of anti-inflammatory modulators of protease-activated receptor 1 (PAR1)
SBIR I 期:蛋白酶激活受体 1 (PAR1) 抗炎调节剂的结构引导设计
  • 批准号:
    2223225
  • 财政年份:
    2023
  • 资助金额:
    $ 33.95万
  • 项目类别:
    Standard Grant
Targeting anti-viral and anti-inflammatory responses during ocular HSV-1 infection to prevent vision impairment.
针对眼部 HSV-1 感染期间的抗病毒和抗炎反应,以预防视力障碍。
  • 批准号:
    10651054
  • 财政年份:
    2023
  • 资助金额:
    $ 33.95万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了